NewBiomed PIKA Pte. Ltd. of Singapore licensed adjuvant vaccine technology to Yunnan Walvax Biotech Co. Ltd., who will seek SFDA approval for the technology in a nasal spray vaccine for influenza and then market it in China. NewBiomed is developing the use of the adjuvant with a proprietary therapeutic Hepatitis B vaccine. The firm also expects to license its PIKA adjuvant technology to two other companies, also for China influenza vaccines.  More details...